This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
INCY Stock Down on Disappointing Skin Disease Study Data
by Zacks Equity Research
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
by Sundeep Ganoria
Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?
by Ekta Bagri
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the stock to investors.
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
by Zacks Equity Research
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
by Zacks Equity Research
Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
by Zacks Equity Research
Data from a mid-stage study shows that treatment with Trevi's experimental drug reduced patients' 24-hour cough frequency by 57% over placebo.
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
by Zacks Equity Research
The latest decision makes Ionis/AstraZeneca's Wainzua the only approved drug in the EU for ATTRv-PN that can be self-administered monthly via an auto-injector.
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
by Zacks Equity Research
Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
by Zacks Equity Research
CMRX and JAZZ are in the spotlight this week following an acquisition agreement.
Theravance's Q4 Loss In Line With Estimates, Sales Beat
by Zacks Equity Research
TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?
by Sundeep Ganoria
Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA stock.
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
by Ekta Bagri
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there is more room for growth and recommend the stock to investors.
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
by Zacks Equity Research
MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
by Zacks Equity Research
Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is trading up.
Bear Of The Day: GSK PLC (GSK)
by Brian Bolan
Healthcare stock investors have been feeling rather sick about the potential changes the Trump Administration may bring.
Kratos Defense and GSK have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Kratos Defense and GSK have been highlighted as Zacks Bull and Bear of the Day.
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
by Zacks Equity Research
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
GSK (GSK) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 11.32% and 4.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline
by Zacks Equity Research
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.